Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IMNN Stock Forecast 2025-2026
$3.90
Current Price
$11.97M
Market Cap
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to IMNN Price Targets
+4,582.3%
To High Target of $182.61
+711.0%
To Median Target of $31.63
+207.7%
To Low Target of $12.00
IMNN Price Momentum
-0.8%
1 Week Change
-2.5%
1 Month Change
-64.4%
1 Year Change
-68.5%
Year-to-Date Change
-90.5%
From 52W High of $41.22
+9.6%
From 52W Low of $3.56
📊 TOP ANALYST CALLS
Did IMNN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Imunon is one of their latest high-conviction picks.
Latest IMNN Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, IMNN has a bullish consensus with a median price target of $31.63 (ranging from $12.00 to $182.61). The overall analyst rating is N/A (N/A/10). Currently trading at $3.90, the median forecast implies a 711.0% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Emily Bodnar at HC Wainwright & Co., suggesting a 207.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMNN Analyst Ratings
3
Buy
1
Hold
0
Sell
IMNN Price Target Range
Low
$12.00
Average
$31.63
High
$182.61
Current: $3.90
Latest IMNN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMNN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2025 | D. Boral Capital | Jason Kolbert | Hold | Downgrade | $N/A |
| May 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $17.00 |
| May 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $14.00 |
| Mar 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Feb 27, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Feb 19, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Jan 24, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Dec 19, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $12.00 |
| Dec 10, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Nov 25, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $29.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $12.00 |
| Nov 7, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $29.00 |
| Oct 31, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $29.00 |
| Sep 23, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $29.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $14.00 |
| Aug 5, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $14.00 |
| May 14, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $12.00 |
Imunon, Inc. (IMNN) Competitors
The following stocks are similar to Imunon based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Imunon, Inc. (IMNN) Financial Data
Imunon, Inc. has a market capitalization of $11.97M with a P/E ratio of -0.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -233.5%.
Valuation Metrics
Market Cap
$11.97M
Enterprise Value
$7.83M
P/E Ratio
-0.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+43.8%
Current Ratio
1.7x
Debt/Equity
27.0x
ROE
-233.5%
ROA
-77.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Imunon, Inc. (IMNN) Business Model
About Imunon, Inc.
What They Do
Develops immunotherapies and DNA-based vaccines.
Business Model
Imunon generates revenue through the development of its innovative immunotherapies and vaccines, including its lead product, IMNN-001, currently in Phase II trials. The company also explores partnerships and funding opportunities as it advances its pipeline of preclinical candidates, which includes vaccines for COVID-19 and therapies for various cancers and viral infections.
Additional Information
Founded in 1982 and based in Lawrenceville, New Jersey, Imunon utilizes proprietary non-viral DNA technology platforms, TheraPlas and PlaCCine, to create targeted immune responses. With its focused pipeline and advanced technology, the company is positioned as a significant player in the biotechnology sector, aiming to address unmet medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
25
CEO
Dr. Stacy R. Lindborg Ph.D.
Country
United States
IPO Year
1999
Website
imunon.comImunon, Inc. (IMNN) Latest News & Analysis
Latest News
Quick Summary
Imunon, Inc. (IMNN) will hold its Q3 2025 earnings call on November 13, 2025, at 11:00 AM EST, featuring key executives including the CEO and CFO.
Why It Matters
The Q3 earnings call for Imunon, Inc. provides insights into the company's financial health and strategic direction, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
R&D Day highlighted positive investigator sentiment and progress in the Phase 3 OVATION 3 Study, aiming to develop the first frontline immunotherapy for advanced ovarian cancer.
Why It Matters
Positive developments in the Phase 3 OVATION 3 Study enhance the potential for a groundbreaking treatment in advanced ovarian cancer, potentially boosting the company's market position and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Imunon, Inc. (IMNN) reviewed the progress of its IMNN-001 immunotherapy in the OVATION 3 ovarian cancer study during a conference call on November 10, 2025.
Why It Matters
Imunon's progress on IMNN-001 in ovarian cancer could signal advancements in immunotherapy, potentially impacting stock value and market perception of the company's growth and innovation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
An event today at 8:00 a.m. ET in NYC will feature presentations on ovarian cancer from experts. Investors and stakeholders can attend in-person or virtually.
Why It Matters
The event signals potential advancements in ovarian cancer treatments, which could impact stock prices and market sentiment for related biotech companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IMUNON, Inc. (Nasdaq: IMNN) held a webcast sharing insights from key opinion leaders on its DNA-mediated immunotherapy, IMNN-001, showing promise for advanced ovarian cancer in Phase 3 trials.
Why It Matters
The webcast reveals promising clinical data for IMUNON's immunotherapy, which could enhance investor confidence and drive stock value if trials succeed in treating advanced ovarian cancer.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
IMUNON, Inc. (Nasdaq: IMNN) will hold a conference call on Nov. 6, 2025, at 11:00 a.m. The company is in Phase 3 development of its DNA-mediated immunotherapy.
Why It Matters
The conference call indicates potential updates on IMUNON's Phase 3 trial, which could impact stock performance and investor sentiment based on progress or results.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IMNN Stock
What is Imunon, Inc.'s (IMNN) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Imunon, Inc. (IMNN) has a median price target of $31.63. The highest price target is $182.61 and the lowest is $12.00.
Is IMNN stock a good investment in 2026?
According to current analyst ratings, IMNN has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMNN stock?
Wall Street analysts predict IMNN stock could reach $31.63 in the next 12 months. This represents a 711.0% increase from the current price of $3.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Imunon, Inc.'s business model?
Imunon generates revenue through the development of its innovative immunotherapies and vaccines, including its lead product, IMNN-001, currently in Phase II trials. The company also explores partnerships and funding opportunities as it advances its pipeline of preclinical candidates, which includes vaccines for COVID-19 and therapies for various cancers and viral infections.
What is the highest forecasted price for IMNN Imunon, Inc.?
The highest price target for IMNN is $182.61 from at , which represents a 4,582.3% increase from the current price of $3.90.
What is the lowest forecasted price for IMNN Imunon, Inc.?
The lowest price target for IMNN is $12.00 from Emily Bodnar at HC Wainwright & Co., which represents a 207.7% increase from the current price of $3.90.
What is the overall IMNN consensus from analysts for Imunon, Inc.?
The overall analyst consensus for IMNN is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $31.63.
How accurate are IMNN stock price projections?
Stock price projections, including those for Imunon, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 1:03 PM UTC